

13 November 2023

Hospital-Acquired Complications: A Comparison of Surveillance and Coding Data

Ms Jaimie Yamada, Ms Shirley Leong, Dr Andrew
Stewardson, Ms Denise Del Rosario-Kelly, Ms Pauline
Bass



the**Alfred**

All contributors declare no conflict of interest

Part of **Alfred**Health

Alfred Health

14 state-wide health services including:

- Major trauma
- Complex adult burns
- Heart/lung transplant
- Extracorporeal membrane oxygenation (ECMO) support for profound heart/lung failure




Background

Hospital-acquired complications (HACs) are identified by coding data

HAC detection through coding data is known to have a low positive predictive value (PPV)

PPV = % of patients with a positive test who actually have the disease

AlfredHealth



The screenshot shows the website of the Australian Commission on Safety and Quality in Health Care. The header is blue with the organization's name in white. A navigation bar below the header contains links: Home, Standards, Our work (highlighted), COVID-19, Publications and resources, and Newsroom. The main content area has a breadcrumb trail: Home > Our work > Indicators, measurement and reporting > Complications. The title 'Hospital-acquired complications (HACs)' is followed by a definition: 'A hospital-acquired complication (HAC) refers to a complication for which clinical risk mitigation strategies may reduce (but not necessarily eliminate) the risk of that complication occurring.' Below this is a section 'On this page:' with links to 'Hospital-acquired complications list', 'Hospital-acquired complications resources', and 'Review'. The 'Hospital-acquired complications list' section is highlighted with a purple border and contains text about the national list of 16 HACs, developed through a process including reviews of literature, clinical engagement, and testing with hospitals.

AUSTRALIAN COMMISSION
ON SAFETY AND QUALITY IN HEALTH CARE

Home Standards Our work COVID-19 Publications and resources Newsroom

[Home](#) > [Our work](#) > [Indicators, measurement and reporting](#) > Complications

Hospital-acquired complications (HACs)

A hospital-acquired complication (HAC) refers to a complication for which clinical risk mitigation strategies may reduce (but not necessarily eliminate) the risk of that complication occurring.

On this page:


- [Hospital-acquired complications list](#)
- [Hospital-acquired complications resources](#)
- [Review](#)

Hospital-acquired complications list


The national list of 16 HACs was developed through a comprehensive process that included:

- Reviews of the literature
- Clinical engagement
- Testing of the concept with public and private hospitals.

Why this is important




**Hospital
funding**



**Known low
PPV**



**Increasing
use of
coding
data**



**High rates
of
infection**

A detailed scanning electron micrograph (SEM) of several rod-shaped bacteria, likely Escherichia coli, showing their textured surface and flagella. The bacteria are arranged in a cluster, with some appearing to be in the process of dividing or budding.

Aim

- Evaluate the PPV of HAC detection
- International Classification of Diseases (ICD) coding data versus traditional surveillance data
- Focus on hospital-acquired pneumonia (HAP) and healthcare-associated urinary tract infections (HA-UTIs)

METHOD

Retrospective analysis at Alfred Health: 50 HAP and 50 HA-UTI coded patients

Timeline

- Review/adapt definitions
- Develop electronic surveillance tool
- 100 patient reviews
- Review findings

Underlying Disease

Does the patient have underlying cardiac or pulmonary disease?

☒ Yes
☐ No

Choose the underlying disease: Underlying pulmonary disease

State the underlying disease: COPD

Imaging

Complete the following date(s) and test type(s) if appropriate:

Test One Date: 05-10-2023 Test One Type: X-ray

Test Two Date: 06-10-2023 Test Two Type: CT-scan

Symptoms

Symptoms?

☒ Yes
☐ No

Symptoms with onset on Day 3 or later (day of admission = Day 1) of the current admission?

☒ Yes
☐ No

Date of symptom onset: 05-10-2023

Did the patient experience at least ONE of the following:

☒ Fever >38°C with no other cause
☐ Leukopenia (WBC <4 10⁹/L)
☐ Leucocytosis (WBC ≥12 10⁹/L)
☐ None of the above

Did the patient experience at least ONE of the following:

☒ New onset of purulent sputum, or change in character of sputum (colour, odour, quantity, consistency)
☐ Cough or dyspnea or tachypnea
☐ Suggestive auscultation (rales or bronchial breath sounds), ronchi, wheezing
☐ Worsening gas exchange (e.g. oxygen desaturation or increased oxygen requirements or increased ventilation demand)
☐ None of the above

Microbiology

Diagnostic test: Bacteriologic diagnostic test

Bacteriologic diagnostic test outcome:

☒ Broncho-alveolar lavage (BAL) with +, ++, or +++ growth
☐ Protected brush with +, ++, or +++ growth
☐ Distal protected aspirate (DPA) with +, ++, or +++ growth
☐ Quantitative culture of LRT specimen (e.g. endotracheal aspirate) with +, ++, or +++ growth
☐ None of the above

Outcome

PN1 confirmed: Positive quantitative c

Data Collection

Was the patient intubated on Day 1 or Day 2 (day of admission = Day 1) of the current admission?

☐ Yes
☐ No

Surveillance definitions

European Centre for Disease Prevention and Control (ECDC)

PN: PNEUMONIA

Rx	Two or more serial chest X-rays or CT-scans with a suggestive image of pneumonia for patients with underlying cardiac or pulmonary disease, and at least one of the following (in patients without underlying cardiac or pulmonary disease one definitive chest X-ray or CT-scan is sufficient):
Symptoms	<ul style="list-style-type: none">• fever $>38^{\circ}\text{C}$ with no other cause;• leukopenia ($<4000 \text{ WBC/mm}^3$) or leucocytosis ($\geq 12\,000 \text{ WBC/mm}^3$); and at least one of the following (or at least two if clinical pneumonia only = PN 4 and PN 5): <ul style="list-style-type: none">– new onset of purulent sputum, or change in character of sputum (colour, odour, quantity, consistency);– cough or dyspnea or tachypnea;– suggestive auscultation (rales or bronchial breath sounds), ronchi, wheezing;– worsening gas exchange (e.g. oxygen desaturation or increased oxygen requirements or increased ventilation demand); and according to the used diagnostic method:
Microbiology	<p>a) Bacteriologic diagnostic test performed by:</p> <ul style="list-style-type: none">• Positive quantitative culture from minimally contaminated LRT (lower respiratory tract) specimen (PN 1):<ul style="list-style-type: none">– broncho-alveolar lavage (BAL) with a threshold of $>10^4 \text{ CFU/ml}$ or $\geq 5\%$ of BAL obtained cells contain intracellular bacteria on direct microscopic exam (classified on the diagnostic category BAL);– protected brush (PB Wimberley) with a threshold of $>10^3 \text{ CFU/ml}$;– distal protected aspirate (DPA) with a threshold of $>10^3 \text{ CFU/ml}$;• Positive quantitative culture from possibly contaminated LRT specimen (PN 2):<ul style="list-style-type: none">– Quantitative culture of LRT specimen (e.g. endotracheal aspirate) with a threshold of 10^5 CFU/ml <p>b) Alternative microbiology methods (PN 3):</p> <ul style="list-style-type: none">• positive blood culture not related to another source of infection;• Positive growth in culture of pleural fluid;• pleural or pulmonary abscess with positive needle aspiration;• histologic pulmonary exam shows evidence of pneumonia;• positive exams for pneumonia with virus or particular germs (<i>Legionella</i>, <i>Aspergillus</i>, mycobacteria, mycoplasma, <i>Pneumocystis carinii</i>):<ul style="list-style-type: none">– positive detection of viral antigen or antibody from respiratory secretions (e.g. EIA, FAMA, shell vial assay, PCR);– positive direct exam or positive culture from bronchial secretions or tissue;– seroconversion (e.g. influenza viruses, <i>Legionella</i>, Chlamydia);– detection of antigens in urine (<i>Legionella</i>). <p>c) Others:</p> <ul style="list-style-type: none">• positive sputum culture or non-quantitative LRT specimen culture (PN 4);• no positive microbiology (PN 5).

Notes:

One definitive chest X-ray or CT-scan for the current pneumonia episode may be sufficient in patients with underlying cardiac or pulmonary disease if comparison with previous X-rays is possible.

PN 1 and PN 2 criteria were validated without previous antimicrobial therapy. However, this does not exclude the diagnosis of PN 1 or PN 2 in the case of previous antimicrobial use.

Comment: The subdivision of the pneumonia definition in five categories allows for the comparison of similar entities of pneumonia within and between countries. It is essential that all hospitals report PN4 and PN5 (clinical pneumonia without microbiological evidence) if appropriate in order to achieve overall comparability, even if a microbiological exam was performed and yielded negative results. It is also advised, both for clinical and surveillance purposes, that networks promote as microbiological confirmation (PN1–3) as a routine practice, at least in the ICU.

Intubation-associated pneumonia (IAP): a pneumonia is defined as intubation-associated (IAP) if an invasive respiratory device was present (even intermittently) in the 48 hours preceding the onset of infection.

PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 6.1

TECHNICAL DOCUMENT

UTI: URINARY TRACT INFECTION

UTI-A: microbiologically confirmed symptomatic UTI

- Patient has at least one of the following signs of symptoms with no other recognised cause: fever ($>38^{\circ}\text{C}$), urgency, frequency, dysuria, or suprapubic tenderness

and

- patient has a positive urine culture, that is, $\geq 10^5$ microorganisms per ml of urine with no more than two species of microorganisms.

UTI-B: not microbiologically confirmed symptomatic UTI

- Patient has at least two of the following with no other recognised cause: fever ($>38^{\circ}\text{C}$), urgency, frequency, dysuria, or suprapubic tenderness,

and

- at least one of the following:
 - positive dipstick for leukocyte esterase and/or nitrate;
 - pyuria urine specimen with $\geq 10 \text{ WBC/ml}$ or $\geq 3 \text{ WBC/high-power field}$ of unspun urine;
 - organisms seen on Gram stain of unspun urine;
 - at least two urine cultures with repeated isolation of the same uropathogen (Gram-negative bacteria or *S. saprophyticus*) with $\geq 10^2$ colonies/ml urine in nonvoided specimens;
 - $\leq 10^5$ colonies/ml of a single uropathogen (Gram-negative bacteria or *S. saprophyticus*) in a patient being treated with effective antimicrobial agent for a urinary infection;
 - physician diagnosis of a urinary tract infection;
 - physician institutes appropriate therapy for a urinary infection.

UTI-C: asymptomatic bacteriuria: EXCLUDED FOR PPS, not to be reported*

- Patient has no fever ($>38^{\circ}\text{C}$), urgency, frequency, dysuria, or suprapubic tenderness

and

either of the following criteria:

- Patient has had an indwelling urinary catheter within seven days before urine is cultured,
- and
- patient has a urine culture, that is, $\geq 10^5$ microorganisms per ml of urine with no more than two species of microorganisms;
 - patient has not had an indwelling urinary catheter within seven days before the first positive culture;
- and
- patient has had at least two positive urine cultures $\geq 10^5$ microorganisms per mm³ of urine with repeated isolation of the same microorganism and no more than two species of microorganisms.

* Note: Bloodstream infections secondary to asymptomatic bacteriuria are reported as BSI with source (origin) S-UTI

Pneumonia: Key Findings

6 patients met HAP surveillance criteria (green)

- PN1 = 1 patient
- PN2 = 3 patients
- PN3 = 2 patients

44 patients did not meet HAP surveillance criteria (red)

- PN4 = 4 patients
- No criteria met = 40 patients




UTI: Key Findings

29 patients met HA-UTI criteria (green)

- UTI-A = 29 patients

21 patients did not meet HA-UTI criteria (red)

- UTI-C (asymptomatic bacteriuria) = 15 patients
- No criteria met = 6 patients



Results

88%

HAP coded patients did not meet
surveillance criteria
(PPV = 12%)


42%

HA-UTI coded patients did not
meet surveillance criteria
(PPV = 58%)

PPV = % of patients with a positive test who actually have the disease

AlfredHealth


Limitations




**Small sample
size**



**Strict surveillance
definitions**




**Subjective
clinical
interpretations**



**Unable to determine
sensitivity, specificity
or negative predictive
value**

Future possibilities



Further validation
and improvement of
current algorithms.



Electronic Medical
Record template to
prompt physicians with
HAP and HA-UTI
diagnostic criteria.




Infection Prevention
surveillance to assist
Clinical Coding team.



Align coding
and surveillance
definitions.

References



1. Australian Commission on Safety and Quality in Healthcare. Hospital-acquired complications (HACs) [Internet]. Canberra ACT: ACSQH; 2019 [cited 2023 Apr 4]. Available from: <https://www.safetyandquality.gov.au/our-work/indicators/hospital-acquired-complications>
2. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD) [Internet]. Geneva: WHO; 2022 [cited 2023 Apr 4]. Available from: <https://www.who.int/standards/classifications/classification-of-diseases>
3. Goto M, Ohl ME, Schweizer ML, Perencevich EN. Accuracy of administrative code data for the surveillance of healthcare-associated infections: a systematic review and meta-analysis. Clin Infect Dis [Internet]. 2014 Mar 1 [cited 2023 Apr 4];58(5):688-96. Available from: <https://academic.oup.com/cid/article/58/5/688/364950> doi: <https://doi.org/10.1093/cid/cit737>
4. Van Mourik MS, van Duijn PJ, Moons KG, Bonten MJ, Lee GM. Accuracy of administrative data for surveillance of healthcare-associated infections: a systematic review. BMJ Open [Internet]. 2015 Aug 1 [cited 2023 Apr 4];5(8):e008424. Available from: <https://bmjopen.bmj.com/content/5/8/e008424.short> doi: <http://dx.doi.org/10.1136/bmjopen-2015-008424>
5. Australian Commission on Safety and Quality in Healthcare. HACs FAQs and resources [Internet]. Canberra ACT: ACSQH; 2019 [cited 2023 Apr 4]. Available from: <https://www.safetyandquality.gov.au/our-work/indicators-measurement-and-reporting/complications/hacs-faqs-and-resources>
6. European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infection and antimicrobial use in European acute care hospitals [Internet]. Stockholm: ECDC; 2022 [cited 2023 Apr 4]. 92 p. Protocol version 6.1.: Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobial-use-healthcare-associated-infections-point-prevalence-survey-version6-1.pdf>
7. Bartley D, Panchasarp R, Bowen S, Deane J, Ferguson JK. How accurately is hospital acquired pneumonia documented for the correct assignment of a hospital acquired complication (HAC)? Infect Dis Health [Internet]. 2021 Feb 1 [cited 2023 Apr 4];26(1):67-71. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S2468045120300675> doi: <https://doi.org/10.1016/j.idh.2020.09.004>
8. Australian Commission on Safety and Quality in Health Care. Antimicrobial prescribing practice in Australian hospitals, results of the 2019 hospital national antimicrobial prescribing survey [Internet]. Sydney: ACSQHC; 2021 [cited 2023 Apr 4]. 45 p. Available from: https://www.safetyandquality.gov.au/sites/default/files/2021-04/report_-_2019_hospital_naps.pdf